A novel uracil analog, 6-chloro-5-(2-propenyl)uracil, preferentially enhances growth inhibition and differentiation of myeloid leukemia cells induced by 1alpha,25-dihydroxyvitamin D3.
The novel uracil analog, 6-chloro-5-(2-propenyl)uracil (TI90), inhibited the growth of myeloid leukemia cells and induced morphologic and functional differentiation of the cells. Although TI90 was a weak inducer of differentiation, it greatly enhanced the growth inhibition and differentiation of the leukemia cells previously induced by 1alpha,25-dihydroxyvitamin D3 (VD3) or all-trans retinoic acid (ATRA). TI90 cooperated with VD3 much more effectively than with ATRA in inhibiting cell growth and inducing differentiation. It also decreased the effective concentration of VD3 to the 10(-10) M level. On the other hand, there was no significant synergy between VD3 and the other uracil analogs. TI90 did not affect VD3 metabolism or the number and affinity of VD3 receptors (VDR) in HL-60 cells. Signals from VD3 are predominantly mediated by VDR and the ligand-activated binding of VDR to vitamin D-responsive element (VDRE) as a heterodimer with the retinoid X receptor (RXR). According to the results of a gel shift assay, TI90 enhanced the intensity of the retarded band with synthetic VDRE oligomer in the presence of VD3, suggesting that TI90 increases the number of phosphorylated receptors by inhibiting phosphatase activity, and also stimulates the formation of a functional complex of VDR with RXR.
Kanatani
Y
Y
Department of Chemotherapy, Saitama Cancer Center Research Institute, Japan.
Makishima
M
M
Ishikawa
I
I
Ogasawara
Y
Y
Kawahara
N
N
Motoyoshi
K
K
Nagata
N
N
Honma
Y
Y
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D002117:Calcitriol / Q000008:administration & dosage*; D002454:Cell Differentiation / Q000187:drug effects*; D002467:Cell Nucleus / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000378:metabolism; D006131:Growth Inhibitors / Q000008:administration & dosage*; D018922:HL-60 Cells; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D009580:Nitroblue Tetrazolium / Q000378:metabolism; D010088:Oxidoreductases / Q000378:metabolism; D018167:Receptors, Calcitriol / Q000378:metabolism; D018168:Receptors, Retinoic Acid / Q000378:metabolism; D047488:Retinoid X Receptors; D014157:Transcription Factors / Q000378:metabolism; D014212:Tretinoin / Q000008:administration & dosage; D014407:Tumor Cells, Cultured; D014498:Uracil / Q000008:administration & dosage* / Q000031:analogs & derivatives*
C110989:6-chloro-5-(2-propenyl)-uracil; D000964:Antimetabolites, Antineoplastic; D004268:DNA-Binding Proteins; D006131:Growth Inhibitors; D018167:Receptors, Calcitriol; D018168:Receptors, Retinoic Acid; D047488:Retinoid X Receptors; D014157:Transcription Factors; D009580:Nitroblue Tetrazolium; D014212:Tretinoin; D014498:Uracil; D010088:Oxidoreductases; D002117:Calcitriol